Olivier Finance

Title: Olivier Finance: Innovator in Adenosine A3 Ligands

Introduction

Olivier Finance is a notable inventor based in Montpellier, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that act as adenosine A3 receptor ligands. His work has implications for various therapeutic applications.

Latest Patents

Olivier Finance holds a patent for "Aminoquinoline and aminopyridine derivatives and their use as adenosine A3 ligands." This patent describes compounds of general formula (I), wherein R and R' stand for a hydrogen atom or can form a 1,3-butadienyl group, which may be substituted by a methylenedioxy group or one or more straight or branched alkyl groups, straight or branched alkoxy groups, hydroxy groups, or halogen atoms. These compounds are recognized as strong adenosine A3 receptor ligands, preferably functioning as antagonists. He has 1 patent to his name.

Career Highlights

Throughout his career, Olivier Finance has worked with prominent companies in the pharmaceutical industry, including Sanofi and Sanofi-Aventis. His experience in these organizations has allowed him to contribute to significant advancements in drug development and innovation.

Collaborations

Olivier has collaborated with esteemed colleagues such as Peter Arányi and László Balázs. Their joint efforts have furthered research in the field of adenosine receptor ligands.

Conclusion

Olivier Finance is a distinguished inventor whose work on adenosine A3 ligands has the potential to impact therapeutic strategies. His contributions to medicinal chemistry and collaborations with industry leaders highlight his importance in the field.